For research use only. Not for therapeutic Use.
KIN1408 is an agonist of the RIG-1-like receptor (RLR) pathway and exhibits a broad-spectrum antiviral activity. KIN1408 exhibits activity against HCV, influenza A, dengue virus 2, Ebola, Nipah, and Lassa viruses[1][2].
KIN1408 has the potency to drive IRF3 activation to induce innate immune gene (MDA5, RIG-1, Mx1, IRF7, and IFIT1 in THP-1 cells) expression and that concomitantly suppress dengue virus2 RNA to levels. KIN1408 also exhibits activity against HCV, influenza A, Ebola, Nipah, and Lassa viruses[1][2].
| Catalog Number | I005756 |
| CAS Number | 1903800-11-2 |
| Synonyms | 7-[[4-(difluoromethoxy)phenyl]-[(5-methoxy-1,3-benzothiazol-2-yl)amino]methyl]quinolin-8-ol |
| Molecular Formula | C25H19F2N3O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C25H19F2N3O3S/c1-32-17-9-11-20-19(13-17)29-25(34-20)30-21(15-4-7-16(8-5-15)33-24(26)27)18-10-6-14-3-2-12-28-22(14)23(18)31/h2-13,21,24,31H,1H3,(H,29,30) |
| InChIKey | YSGBFDHVEQJPPX-UHFFFAOYSA-N |
| SMILES | COC1=CC2=C(C=C1)SC(=N2)NC(C3=CC=C(C=C3)OC(F)F)C4=C(C5=C(C=CC=N5)C=C4)O |
| Reference | [1]. Green RR, et al. Transcriptional analysis of antiviral small molecule therapeutics as agonists of the RLR pathway. Genom Data. 2016 Feb 1;7:290-2. [2]. Sowmya Pattabhi, et al. Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway. J Virol. 2015 Dec 16;90(5):2372-87. |
